Management of TB cases falls short of international standards

The management of tuberculosis cases in the European Union (EU) is not meeting international standards, according to new research.

The research, published online ahead of print in the , has identified key areas of priority for public action to combat the growing number of drug-resistant tuberculosis cases.

The (WHO) estimates a prevalence of 440,000 multidrug-resistant TB cases (MDR-TB) with 150,000 deaths and 50,000 extremely drug-resistant tuberculosis (XDR-TB) cases. The emergence of resistant forms of tuberculosis can in part be attributed to the of the disease.

To help understand how these forms of the disease have emerged, the authors aimed to evaluate the extent of inappropriate TB case management in Europe. To achieve this they conducted a survey, funded by the European Centre for and Control (ECDC). The survey included questions devised by an and compared the answers to a number of internationally recognised guidelines on prevention, diagnosis and treatment of the disease.

The study used data on 200 from five TB reference institutes in five EU countries. The findings revealed that standards are not being adequately met in both the treatment and monitoring of patients.

10% of patients were prescribed less than the four drugs which are recommended and were therefore not sufficiently treated. Furthermore, various errors were identified in the doses of anti-TB drugs which were prescribed. The results also highlighted that patients infected with HIV alongside TB were not satisfactorily managed in almost 34% of cases.

For the monitoring of patients, there was a lack of information on the health of discharged patients with no final outcomes recorded for 32% of patients.

Dr G.B. Migliori, one of the lead authors of the study, said: "MDR-TB is a man-made product and every error in treating a case of MDR-TB can be seen as potential for generating a new MDR-TB case. The results of this study have identified a number of mistakes and deviations from the recommended practices in the management of TB and MDR-TB/XDR-TB cases in Europe. To help prevent the further emergence of drug-resistant TB, we must increase awareness and training, promote standards of care and allocate appropriate resources where necessary."

Provided by European Lung Foundation

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Drug-resistant tuberculosis rife in China

Dec 11, 2008

Levels of drug-resistant tuberculosis (TB) in China are nearly twice the global average. Nationwide research published in the open access journal BMC Infectious Diseases has shown that almost 10% of Chinese TB cases are re ...

WHO warns of drug-resistant TB

Sep 06, 2006

The World Health Organization in Switzerland has warned of a new strain of tuberculosis that is rapidly spreading and cannot be treated with current drugs.

Recommended for you

Senegal monitors contacts of 1st Ebola patient

11 hours ago

Senegalese authorities on Monday were monitoring everyone who was in contact with a student infected with Ebola who crossed into the country, and who has lost three family members to the disease.

Cerebral palsy may be hereditary

17 hours ago

Cerebral palsy is a neurological developmental disorder which follows an injury to the immature brain before, during or after birth. The resulting condition affects the child's ability to move and in some ...

19 new dengue cases in Japan, linked to Tokyo park

23 hours ago

Japan is urging local authorities to be on the lookout for further outbreaks of dengue fever, after confirming another 19 cases that were contracted at a popular local park in downtown Tokyo.

User comments